These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36745746)

  • 1. Strategies of Targeting CK2 in Drug Discovery: Challenges, Opportunities, and Emerging Prospects.
    Chen Y; Wang Y; Wang J; Zhou Z; Cao S; Zhang J
    J Med Chem; 2023 Feb; 66(4):2257-2281. PubMed ID: 36745746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-guided discovery of adenosine triphosphate-competitive casein kinase 2 inhibitors.
    Patel S; Vyas VK; Sharma M; Ghate M
    Future Med Chem; 2023 Jun; 15(11):987-1014. PubMed ID: 37307219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule modulators targeting protein kinase CK1 and CK2.
    Qiao Y; Chen T; Yang H; Chen Y; Lin H; Qu W; Feng F; Liu W; Guo Q; Liu Z; Sun H
    Eur J Med Chem; 2019 Nov; 181():111581. PubMed ID: 31400711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemically induced degradation of CK2 by proteolysis targeting chimeras based on a ubiquitin-proteasome pathway.
    Chen H; Chen F; Liu N; Wang X; Gou S
    Bioorg Chem; 2018 Dec; 81():536-544. PubMed ID: 30245235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation.
    Perea SE; Baladrón I; Valenzuela C; Perera Y
    Semin Oncol; 2018 Jan; 45(1-2):58-67. PubMed ID: 30318085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies.
    Gowda C; Sachdev M; Muthusami S; Kapadia M; Petrovic-Dovat L; Hartman M; Ding Y; Song C; Payne JL; Tan BH; Dovat S
    Curr Pharm Des; 2017; 23(1):95-107. PubMed ID: 27719640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based identification of novel CK2 inhibitors with a linear 2-propenone scaffold as anti-cancer agents.
    Qi X; Zhang N; Zhao L; Hu L; Cortopassi WA; Jacobson MP; Li X; Zhong R
    Biochem Biophys Res Commun; 2019 Apr; 512(2):208-212. PubMed ID: 30878184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances in the Discovery of CK2 Allosteric Inhibitors: From Traditional Screening to Structure-Based Design.
    Chen X; Li C; Wang D; Chen Y; Zhang N
    Molecules; 2020 Feb; 25(4):. PubMed ID: 32079098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein Kinase CK2, a Potential Therapeutic Target in Carcinoma Management.
    Lian H; Su M; Zhu Y; Zhou Y; Soomro SH; Fu H
    Asian Pac J Cancer Prev; 2019 Jan; 20(1):23-32. PubMed ID: 30677865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein kinase CK2 inhibitors: emerging anticancer therapeutic agents?
    Bortolato A; Cozza G; Moro S
    Anticancer Agents Med Chem; 2008 Oct; 8(7):798-806. PubMed ID: 18855581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATP site-directed inhibitors of protein kinase CK2: an update.
    Sarno S; Papinutto E; Franchin C; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Orzeszko A; Zanotti G; Battistutta R; Pinna LA
    Curr Top Med Chem; 2011; 11(11):1340-51. PubMed ID: 21513497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Casein Kinase II: an attractive target for anti-cancer drug design.
    Hanif IM; Hanif IM; Shazib MA; Ahmad KA; Pervaiz S
    Int J Biochem Cell Biol; 2010 Oct; 42(10):1602-5. PubMed ID: 20558317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
    Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
    Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein kinase CK2 inhibitors: a patent review.
    Cozza G; Pinna LA; Moro S
    Expert Opin Ther Pat; 2012 Sep; 22(9):1081-97. PubMed ID: 22908959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds.
    Hou Z; Nakanishi I; Kinoshita T; Takei Y; Yasue M; Misu R; Suzuki Y; Nakamura S; Kure T; Ohno H; Murata K; Kitaura K; Hirasawa A; Tsujimoto G; Oishi S; Fujii N
    J Med Chem; 2012 Mar; 55(6):2899-903. PubMed ID: 22339433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel small molecule protein kinase CK2 inhibitors exert potent antitumor effects on T98G and SEGA cells in vitro.
    Pucko E; Ostrowski R; Matyja E
    Folia Neuropathol; 2019; 57(3):239-248. PubMed ID: 31588710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repressing the activity of protein kinase CK2 releases the brakes on mitochondria-mediated apoptosis in cancer cells.
    Hanif IM; Pervaiz S
    Curr Drug Targets; 2011 Jun; 12(6):902-8. PubMed ID: 21269261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Pathways: Emergence of Protein Kinase CK2 (CSNK2) as a Potential Target to Inhibit Survival and DNA Damage Response and Repair Pathways in Cancer Cells.
    Rabalski AJ; Gyenis L; Litchfield DW
    Clin Cancer Res; 2016 Jun; 22(12):2840-7. PubMed ID: 27306791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2.
    Duncan JS; Litchfield DW
    Biochim Biophys Acta; 2008 Jan; 1784(1):33-47. PubMed ID: 17931986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response.
    Chen F; Huang X; Wu M; Gou S; Hu W
    Cancer Lett; 2017 Jan; 385():168-178. PubMed ID: 27793693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.